Suchergebnisse - "Guillaume, Thierry"

PubPharm (16)

1

Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients

enthalten in: Hematological oncology | 2022

von Chevallier, P. | Jullien, M. | Peterlin, P. | +5

2

Assessment of COVID-19 Incidence and Severity Among Recipients of Allogenic Stem Cell Transplant After 1 or 2 mRNA Booster Doses During the Omicron Wave in France

enthalten in: JAMA network open | 2022

von Letailleur, V. | Le Bourgeois, A. | Guillaume, T. | +4

3

Efficacy of anti-severe acute respiratory syndrome coronavirus 2 mRNA vaccines in adults with severe acquired aplastic anemia with or without allogeneic hematopoietic stem cell transplantation

enthalten in: EJHaem | 2022

von Garnier, A. | Bourgeois, A. | Guillaume, T. | +5

4

Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients

enthalten in: Cells | 2022

von Clémenceau, B. | Le Bourgeois, A. | Guillaume, T. | +8

5

Anti-SARS-CoV-2 vaccines in recipient and/or donor before allotransplant

enthalten in: EJHaem | 2022

von Jullien, M. | Coste-Burel, M. | Clemenceau, B. | +13

6

B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

enthalten in: Transplantation and cellular therapy | 2022

von Jullien, M. | Le Bourgeois, A. | Coste-Burel, M. | +17

7

Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant

enthalten in: British journal of haematology | 2022

von Le Bourgeois, A. | Coste-Burel, M. | Guillaume, T. | +17

8

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine

enthalten in: Vaccines | 2022

von Clémenceau, B. | Guillaume, T. | Coste-Burel, M. | +9

9

Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy

enthalten in: British journal of haematology | 2022

von Gastinne, T. | Le Bourgeois, A. | Coste-Burel, M. | +17

10

Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy

enthalten in: British Journal of Haematology | 2022

von Gastinne, T. | Le Bourgeois, A. | Coste‐Burel, M. | +17